Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Subscribe To Our Newsletter & Stay Updated